Aspartic and malic acid inhibition of beta-glucuronidase

Disclosed herein are infant dietary supplements containing L-aspartic and/or L-malic acid. The supplements are designed to inhibit beta-glucuronidase activity in breast feeding babies, and thereby suppress serum bilirubin levels and the incidence of neonate jaundice. In one form L-aspartic acid is m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GLENN R. GOURLEY, BILL L. KREAMER
Format:	Patent
Sprache:	eng
Schlagworte:	DAIRY PRODUCTS, e.g. MILK, BUTTER, CHEESE FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE MAKING THEREOF MEDICAL OR VETERINARY SCIENCE MILK OR CHEESE SUBSTITUTES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed herein are infant dietary supplements containing L-aspartic and/or L-malic acid. The supplements are designed to inhibit beta-glucuronidase activity in breast feeding babies, and thereby suppress serum bilirubin levels and the incidence of neonate jaundice. In one form L-aspartic acid is mixed with human breast milk and fed to the neonate on the same schedule that breast feeding would otherwise normally occur. In another form the L-aspartic acid is delivered in an aqueous solution supplemented with sodium and potassium.